These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

203 related articles for article (PubMed ID: 21473199)

  • 21. Tazarotene gel is safe and effective in the treatment of acne vulgaris: a multicenter, double-blind, vehicle-controlled study.
    Shalita AR; Chalker DK; Griffith RF; Herbert AA; Hickman JG; Maloney JM; Miller BH; Tschen EH; Chandraratna RA; Gibson JR; Lew-Kaya DA; Lue JC; Sefton J
    Cutis; 1999 Jun; 63(6):349-54. PubMed ID: 10388959
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Comparison of tazarotene and minocycline maintenance therapies in acne vulgaris: a multicenter, double-blind, randomized, parallel-group study.
    Leyden J; Thiboutot DM; Shalita AR; Webster G; Washenik K; Strober BE; Shupack J
    Arch Dermatol; 2006 May; 142(5):605-12. PubMed ID: 16702498
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Topical Tazarotene Gel, 0.1%, as a Novel Treatment Approach for Atrophic Postacne Scars: A Randomized Active-Controlled Clinical Trial.
    Afra TP; Razmi T M; Narang T; Dogra S; Kumar A
    JAMA Facial Plast Surg; 2019 Mar; 21(2):125-132. PubMed ID: 30452511
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Comparison of treatment of acne vulgaris with alternate-day applications of tazarotene 0.1% gel and once-daily applications of adapalene 0.1% gel: a randomized trial.
    Leyden J; Lowe N; Kakita L; Draelos Z
    Cutis; 2001 Jun; 67(6 Suppl):10-6. PubMed ID: 11499327
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Tazarotene versus tazarotene plus clindamycin/benzoyl peroxide in the treatment of acne vulgaris: a multicenter, double-blind, randomized parallel-group trial.
    Tanghetti E; Abramovits W; Solomon B; Loven K; Shalita A
    J Drugs Dermatol; 2006 Mar; 5(3):256-61. PubMed ID: 16573259
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Is switching retinoids a sound strategy for the treatment of acne vulgaris?
    Gold LS; Colón LE; Johnson LA; Gottschalk RW
    J Drugs Dermatol; 2008 Jun; 7(6 Suppl):s11-7. PubMed ID: 18575221
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Clinical pharmacokinetics and drug metabolism of tazarotene: a novel topical treatment for acne and psoriasis.
    Tang-Liu DD; Matsumoto RM; Usansky JI
    Clin Pharmacokinet; 1999 Oct; 37(4):273-87. PubMed ID: 10554045
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A comparison of tazarotene 0.1% gel once daily plus mometasone furoate 0.1% cream once daily versus calcipotriene 0.005% ointment twice daily in the treatment of plaque psoriasis.
    Guenther LC; Poulin YP; Pariser DM
    Clin Ther; 2000 Oct; 22(10):1225-38. PubMed ID: 11110233
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Clindamycin phosphate 1.2%-benzoyl peroxide (5% or 2.5%) plus tazarotene cream 0.1% for the treatment of acne.
    Dhawan SS; Gwazdauskas J
    Cutis; 2013 Feb; 91(2):99-104. PubMed ID: 23513559
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Tazarotene cream for postinflammatory hyperpigmentation and acne vulgaris in darker skin: a double-blind, randomized, vehicle-controlled study.
    Grimes P; Callender V
    Cutis; 2006 Jan; 77(1):45-50. PubMed ID: 16475496
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Novel Polymeric Lotion Formulation of Once-Daily Tazarotene (0.045%) for Moderate-to-Severe Acne: Pooled Phase 3 Analysis.
    Tanghetti EA; Werschler WP; Lain E; Guenin E; Harris S; Loncaric A; Pillai R
    J Drugs Dermatol; 2020 Mar; 19(3):272-279. PubMed ID: 32549090
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Tazarotene 0.045% Lotion for Females With Acne: Analysis of Two Adult Age Groups.
    Stein Gold L; Kircik L; Baldwin H; Callender V; Tanghetti E; Del Rosso J; Zeichner J; Cook-Bolden F; Guenin E
    J Drugs Dermatol; 2022 Jun; 21(6):587-595. PubMed ID: 35674760
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The only topical retinoid without a generic alternative: tazarotene.
    Kircik LH
    J Drugs Dermatol; 2013 Mar; 12(3):s52. PubMed ID: 23545934
    [No Abstract]   [Full Text] [Related]  

  • 34. Comparison of clinical efficacy of topical tazarotene 0.1% cream with topical clobetasol propionate 0.05% cream in chronic plaque psoriasis: a double-blind, randomized, right-left comparison study.
    Angelo JS; Kar BR; Thomas J
    Indian J Dermatol Venereol Leprol; 2007; 73(1):65. PubMed ID: 17319037
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Once-Daily Polymeric Tazarotene 0.045% Lotion for Moderate-to-Severe Acne: Pooled Phase 3 Analysis by Sex.
    Kircik LH; Gold LS; Beer K; Tan J; Baldwin H; Guenin E; Kang R; Varughese J
    J Drugs Dermatol; 2020 Aug; 19(8):777-783. PubMed ID: 32845584
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Cumulative irritancy comparison of topical retinoid and antimicrobial combination therapies.
    Dosik JS; Gilbert RD; Arsonnaud S
    Skinmed; 2006; 5(5):219-23. PubMed ID: 16957432
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Tazarotene foam versus tazarotene gel: a randomized relative bioavailability study in acne vulgaris.
    Jarratt M; Werner CP; Alió Saenz AB
    Clin Drug Investig; 2013 Apr; 33(4):283-9. PubMed ID: 23456673
    [TBL] [Abstract][Full Text] [Related]  

  • 38. New Polymeric Once-Daily Tazarotene 0.045% Lotion Formulation for Moderate-to-Severe Acne: Pooled Phase 3 Pediatric Analysis.
    Eichenfield LF; Tanghetti EA; Guenin E; Martin G; Pillai R
    J Drugs Dermatol; 2020 Jun; 19(6):602-610. PubMed ID: 32574011
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Optimizing treatment with topical tazarotene.
    Guenther LC
    Am J Clin Dermatol; 2003; 4(3):197-202. PubMed ID: 12627995
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Efficacy and Safety of Tazarotene 0.045% Lotion in Caucasian Adults With Moderate-to-Severe Acne.
    Del Rosso J; Stein Gold L; Tyring S; Zeichner J; Callender V; Draelos Z; Werschler W; Cook-Bolden F; Guenin E
    J Drugs Dermatol; 2022 Oct; 21(10):1061-1069. PubMed ID: 36219057
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.